House Passes 2026 Farm Bill Without Delaying November Hemp THC Ban
The 224-200 vote advances agriculture policy but leaves hemp-derived THC products on track for a November 12 reckoning.
By CBDWorldNews Editorial Staff | May 4, 2026
The U.S. House of Representatives voted 224-200 on April 30 to pass the Farm, Food, and National Security Act of 2026. The bill addresses a wide range of agricultural and food policies, but for the hemp industry, the most notable feature is what it does not include: any delay of the federal ban on hemp-derived THC products set to take effect November 12.
The Continuing Appropriations and Extensions Act, signed into law in November 2025, redefined hemp to include a total THC limit — not just delta-9 — of 0.3% on a dry weight basis, with finished products capped at 0.4 milligrams of total THC per container. That definition takes effect later this year, and the new Farm Bill does nothing to push back that deadline.
What the Farm Bill Does for Hemp
The legislation is not entirely bad news for hemp growers. Several provisions aim to reduce the regulatory burden on industrial hemp producers.
The bill allows the USDA to reduce or eliminate testing requirements for hemp crops. Background check mandates for hemp farmers could also be loosened. Funding for hemp research programs received modest increases. State hemp plans would get a streamlined approval process.
These changes primarily benefit farmers growing hemp for fiber, grain, and seed — the industrial side of the business that pre-dates the CBD boom.
What It Means for CBD and THC Products
The November deadline looms large. The U.S. Hemp Roundtable estimates that the amended hemp definition would eliminate roughly 95% of existing hemp-derived cannabinoid products. The group projects job losses of more than 300,000 positions and the disappearance of over $1.5 billion in state tax revenue.
“The clock is ticking, and Congress just passed on its best opportunity to buy the industry more time.”
Industry advocates had pushed for language in the Farm Bill that would either delay the November implementation or create a regulatory pathway for hemp-derived cannabinoid products. Neither made it into the final text.
Some hemp organizations argue the new definition is so narrow that even many non-intoxicating products — including some traditional CBD oils and tinctures — may fall out of compliance when the cap takes effect.
The Senate Path Forward
The bill now moves to the Senate, where hemp provisions could still change. Several senators from hemp-producing states have signaled interest in addressing the November deadline, though no specific amendment language has been introduced.
Senate Agriculture Committee leaders have their own version of the Farm Bill in development. Whether it includes hemp-friendly provisions will depend on negotiations that are just getting started.
The legislative calendar adds pressure. With the November 12 deadline approaching, any meaningful change to the hemp definition would need to pass both chambers and reach the president’s desk within months.
Industry Response
Hemp industry groups responded to the House vote with a mix of pragmatism and urgency.
Trade associations acknowledged the industrial hemp provisions as positive steps while stressing that the THC product question remains the existential threat facing most of their members.
Several CBD brands have already begun reformulating products to meet the stricter standards. Others are exploring whether their existing products might qualify under the new definition’s narrow parameters. Consumers looking for compliant products should prioritize brands that publish current certificates of analysis showing total THC levels.
For pet CBD products, the picture is similarly uncertain. The new federal definition applies to animal products as well, meaning pet CBD formulations face the same compliance challenges.
What Comes Next
The next six months will be critical. The Senate must act on its own Farm Bill version. Standalone hemp legislation could surface as an alternative. And the FDA’s evolving guidance on CBD products adds another layer of uncertainty.
For now, the industry operates in a shrinking window. Products remain legal under current law, but every week without legislative relief makes the November transition more disruptive.
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.
